How Veracyte’s Profit Jump and 2026 Outlook Will Impact Veracyte (VCYT) Investors

Simply Wall St.03-01 16:17

Veracyte, Inc. recently reported its fourth-quarter and full-year 2025 results, with revenue rising to US$140.64 million in Q4 and US$517.15 million for the year, alongside a jump in net income to US$...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616821367?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-01 16:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616821367","market":"us","top_or_hot":-1,"title":"How Veracyte’s Profit Jump and 2026 Outlook Will Impact Veracyte (VCYT) Investors","media":"Simply Wall St.","content":"<div>\n<p>Veracyte, Inc. recently reported its fourth-quarter and full-year 2025 results, with revenue rising to US$140.64 million in Q4 and US$517.15 million for the year, alongside a jump in net income to US$...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/how-veracytes-profit-jump-and-2026-outlook-will-impact-verac\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Veracyte’s Profit Jump and 2026 Outlook Will Impact Veracyte (VCYT) Investors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Veracyte’s Profit Jump and 2026 Outlook Will Impact Veracyte (VCYT) Investors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-01 16:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/how-veracytes-profit-jump-and-2026-outlook-will-impact-verac><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Veracyte, Inc. recently reported its fourth-quarter and full-year 2025 results, with revenue rising to US$140.64 million in Q4 and US$517.15 million for the year, alongside a jump in net income to US$...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/how-veracytes-profit-jump-and-2026-outlook-will-impact-verac\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ISBC","symbol_name":"投资者银行","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/how-veracytes-profit-jump-and-2026-outlook-will-impact-verac","article_id":"2616821367","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/how-veracytes-profit-jump-and-2026-outlook-will-impact-verac","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616821367","pubTimestamp":1772353042,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Veracyte, Inc. recently reported its fourth-quarter and full-year 2025 results, with revenue rising to US$140.64 million in Q4 and US$517.15 million for the year, alongside a jump in net income to US$41.15 million for the quarter and US$66.35 million for 2025.\nThe company reaffirmed its 2026 revenue guidance of US$570 million to US$582 million and highlighted two upcoming cancer diagnostics launches, TRUE MRD for bladder cancer and Prosigna for early-stage breast cancer, as key growth...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ISBC":"投资者银行","BK4211":"区域性银行","BK4139":"生物科技","VCYT":"Veracyte Inc"},"translate_title":"Veracyte的利润增长和2026年前景将如何影响Veracyte(VCYT)投资者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":1.5,"ISBC":1.5},"content_text":"Veracyte, Inc. recently reported its fourth-quarter and full-year 2025 results, with revenue rising to US$140.64 million in Q4 and US$517.15 million for the year, alongside a jump in net income to US$41.15 million for the quarter and US$66.35 million for 2025. The company reaffirmed its 2026 revenue guidance of US$570 million to US$582 million and highlighted two upcoming cancer diagnostics launches, TRUE MRD for bladder cancer and Prosigna for early-stage breast cancer, as key growth drivers for its testing franchise. We’ll now examine how Veracyte’s stronger profitability and reaffirmed 2026 revenue guidance influence the existing investment narrative around the stock. AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementVeracyte Investment Narrative RecapTo own Veracyte, you need to believe its core cancer tests (Decipher and Afirma) can keep driving profitable growth while new launches like TRUE MRD and Prosigna gradually broaden the franchise. The latest results, with higher profitability and reaffirmed 2026 revenue guidance of US$570 million to US$582 million, support that thesis and appear to modestly strengthen the near term product launch catalyst, while not fundamentally changing the key risk around reimbursement and payer coverage for both existing and upcoming tests. The most relevant recent update here is Veracyte’s decision to reiterate its 2026 revenue outlook of 10% to 13% growth, or US$570 million to US$582 million, excluding any contribution from new tests. In the context of TRUE MRD for bladder cancer and Prosigna for early stage breast cancer, this suggests management is framing these launches as upside to an already profitable core business, which matters for investors who see new indications and MRD testing as the main medium term catalyst. Yet beneath the headline growth, investors should still be aware of how concentrated revenues remain in Decipher and Afirma and how exposed they are to... Read the full narrative on Veracyte (it's free!)Veracyte’s narrative projects $629.2 million revenue and $121.9 million earnings by 2028.Uncover how Veracyte's forecasts yield a $47.50 fair value, a 30% upside to its current price.Exploring Other PerspectivesVCYT 1-Year Stock Price Chart Some of the most optimistic analysts were already assuming Veracyte could reach about US$660 million of revenue and US$155 million of earnings by 2028, which paints a far rosier picture than the more cautious focus on pricing pressure and ASP compression; after this earnings beat and reaffirmed 2026 guidance, you may find that both the bullish and more conservative views evolve in different ways.Explore 5 other fair value estimates on Veracyte - why the stock might be worth 34% less than the current price!Decide For YourselfDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Veracyte research is our analysis highlighting 4 key rewards that could impact your investment decision.Our free Veracyte research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Veracyte's overall financial health at a glance.Seeking Other Investments?Opportunities like this don't last. These are today's most promising picks. Check them out now:The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Invest in the nuclear renaissance through our list of 84 elite nuclear energy infrastructure plays powering the global AI revolution.Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616821367","isCrawlerRequest":true}